Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging-Reference-Cited by-同舟云学术

Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging

Published:2021-03-23 Issue:11 Volume:63 Page:1811-1822
ISSN:0028-3940
Container-title:Neuroradiology
language:en
Short-container-title:Neuroradiology

Author:

Park Yae Won,Ahn Sung Soo^ORCID,Moon Ju Hyung,Kim Eui Hyun,Kang Seok-Gu,Chang Jong Hee,Kim Se Hoon,Lee Seung-Koo

Funder

Korea Basic Science Institute

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Neurology (clinical),Radiology, Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s00234-021-02693-z.pdf

Reference36 articles.

1. Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72(8):1909–1914. https://doi.org/10.1158/0008-5472.Can-11-3406

2. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573

3. Wen PY, Norden AD, Drappatz J, Quant E (2010) Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 12(1):68–75. https://doi.org/10.1007/s11912-009-0078-3

4. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252(1):182–189. https://doi.org/10.1148/radiol.2521081534

5. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF (2017) Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials. Clin Cancer Res 23(19):5745–5756. https://doi.org/10.1158/1078-0432.Ccr-16-2844

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy;European Journal of Nuclear Medicine and Molecular Imaging;2024-01-17

2. Radiomics characterization of tissues in an animal brain tumor model imaged using dynamic contrast enhanced (DCE) MRI;Scientific Reports;2023-07-02

3. Dynamic contrast enhanced (DCE) MRI estimation of vascular parameters using knowledge-based adaptive models;Scientific Reports;2023-06-14

4. Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update;International Journal of Molecular Sciences;2023-03-28

5. Dynamic Contrast Enhanced (DCE) MRI Estimation of Vascular Parameters using Knowledge-Based Adaptive Models;2023-01-04